Study of obinutuzumab-based treatment for untreated follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This real-world study looks at how well obinutuzumab-based treatment works for people with newly diagnosed follicular lymphoma. It is meant for patients whose cancer is measurable on scans and who are eligible for specific standard treatment combinations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have follicular lymphoma (grades 1, 2, or 3A) confirmed by pathology (a lab test on tissue)
- Your lymphoma is CD20-positive (a test result on the cancer cells)
- You have not had lymphoma treatment before
- You are at least 18 years old
- You have a CT or PET-CT scan showing measurable spots of lymphoma before starting treatment
- Your doctors believe you can receive one of these planned regimens: GR, GB, or G-CHOP
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people with a specific high-risk form of follicular lymphoma who have not yet been treated. The goal is to see if this combination can control the lymphoma more effectively.
This study looks at giving obinutuzumab together with lenalidomide to adults whose follicular lymphoma has come back or did not respond well to prior treatment. It may help control the cancer after relapse or resistance to standard therapies.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This study tests whether adding obinutuzumab (an antibody medicine) to local radiation works better than radiation alone in early-stage follicular lymphoma. It aims to improve disease control while keeping treatment safe.
This trial tests a combination of two targeted drugs, zanubrutinib and obinutuzumab, for people who have just been diagnosed with follicular lymphoma. The goal is to see if this combination works well and is safe.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.